VAXCYTE, INC. Tax Withholding Paid on Stock Awards
VAXCYTE, INC. (PCVX) reported Tax Withholding Paid on Stock Awards of $11.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-05
- VAXCYTE, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-06-30 was $2.06M, a 187.31% increase year-over-year.
- VAXCYTE, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2026-03-31 was $9.29M, a 75.71% increase year-over-year.
- VAXCYTE, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $1.01M, a 7.19% decline year-over-year.
- VAXCYTE, INC. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $3.98M, a 57.40% decline year-over-year.
- VAXCYTE, INC. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $10.99M, a 23.10% decline from fiscal 2024.
- VAXCYTE, INC. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $14.29M, a 268.73% increase from fiscal 2023.
- VAXCYTE, INC. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $3.88M, a 350.17% increase from fiscal 2022.
- VAXCYTE, INC. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $861.00K.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $11.36M 10-Q · filed 2026-08-05 | $12.36M derived: sum of 3 quarters · filed 2026-08-05 | $16.34M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $9.29M 10-Q · filed 2026-05-06 | $10.30M derived: sum of 2 quarters · filed 2026-05-06 | $14.28M derived: sum of 3 quarters · filed 2026-05-06 | $15.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $4.98M derived: sum of 2 quarters · filed 2026-02-24 | $5.70M derived: sum of 3 quarters · filed 2026-08-05 | $10.99M 10-K · filed 2026-02-24 |
| 2025-09-30 | $3.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.69M derived: sum of 2 quarters · filed 2026-08-05 | $9.98M 10-Q · filed 2025-11-04 | $11.07M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $717.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $6.01M 10-Q · filed 2026-08-05 | $7.09M derived: sum of 3 quarters · filed 2026-08-05 | $16.43M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $5.29M 10-Q · filed 2026-05-06 | $6.38M derived: sum of 2 quarters · filed 2026-05-06 | $15.71M derived: sum of 3 quarters · filed 2026-05-06 | $16.28M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $10.42M derived: sum of 2 quarters · filed 2026-02-24 | $10.99M derived: sum of 3 quarters · filed 2026-02-24 | $14.29M 10-K · filed 2026-02-24 |
| 2024-09-30 | $9.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $9.90M derived: sum of 2 quarters · filed 2025-11-04 | $13.21M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $565.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $3.87M 10-Q · filed 2025-08-06 | ||
| 2024-03-31 | $3.31M 10-Q · filed 2025-05-07 | |||
| 2023-12-31 | $3.88M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $861.00K 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |